

Human Papillomavirus Vaccine Program Summary

(Vaccine and Antigen Code: HPV-9)

Inactivated Vaccine

Biological	Indications	Schedule	Specific Contraindications	Expected Reactions
<p>Human Papillomavirus</p> <p>Merck Gardasil -9® Includes HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58. (licensed for females 9 – 45 years of age inclusive and males 9 – 26 years inclusive)</p> <p>Goals: 95% of Grade 6 students.</p> <p>Vaccine Program History</p> <ul style="list-style-type: none"> • Grade 5 HPV-4 school program for girls started in 2008-2009. • 3 year grade 9 catch-up program for girls: 2009/2010 to 2011/2012. • Grade 5 HPV-4 school program for boys started 2014/2015. • 4 year grade 9 catch-up program for boys: 2014/2015 to 2017/2018. • HPV-9 replaced HPV-4 Sept 1, 2016 (i.e. 2016/2017 school year). • Feb 2018 MSM included in eligibility • Sept 2018: schedule change to Grade 6 from Grade 5. • Sept 2018: schedule changed to 2 doses from 3 doses for immunocompetent and non HIV clients 9–14 years of age (inclusive). 	<p>Universal Program:</p> <ul style="list-style-type: none"> • all Grade 6 students (starts Fall 2018) • Male individuals aged 17 – 26 years of age who have sex with men. • Hematopoietic Stem Cell transplant recipients and solid organ transplant candidates/recipients may be eligible, call CDC team. <p>Notes:</p> <ul style="list-style-type: none"> • The number of doses in a series is based on the age at administration of the first dose and if they are immunocompetent or immunocompromised. • Students continue to be eligible for HPV vaccine until the end of grade 12. If in ungraded classes or not in school, eligible from 11 through 18 years of age. • Students who began their series with HPV-4 can complete series with HPV-9. • An interrupted schedule does not require restarting. 	<p>Immunocompetent and non-HIV infected individuals 9 – 14 years of age (inclusive):</p> <ul style="list-style-type: none"> • 2 dose series given: day 0, 6 months. <p>Immunocompromised and/or HIV infected individuals 9 – 14 years of age (inclusive):</p> <ul style="list-style-type: none"> • 3 dose series: day 0, 2 months, 6 months. <p>Individuals 15 years of age and older:</p> <ul style="list-style-type: none"> • 3 dose series given at 0, 2 months, and 6 months <p>Minimum Spacing Guidelines For Children Off Schedule:</p> <ul style="list-style-type: none"> • In a two dose schedule, <ul style="list-style-type: none"> • min. of 24 weeks between the 1st and 2nd doses • In a three dose schedule, <ul style="list-style-type: none"> • min. of 4 weeks between the 1st and 2nd doses • min. of 12 weeks between the 2nd and 3rd doses and 24 weeks between the 1st and 3rd dose. • When reviewing charts, the 3rd dose can be considered valid if there is at least 16 weeks between 1st and 3rd doses: do not use this to plan schedule. <p>Dose: 0.5 ml given IM</p>	<p>Anaphylactic reaction to previous dose of vaccine or any component of the vaccine.</p> <p>Should not be given to Pregnant women. Remaining doses should be deferred until after delivery.</p>	<p>Very Common: (≥10%)</p> <ul style="list-style-type: none"> • Injection site pain, redness, swelling, and itchiness, bruising, mass, bleeding. <p>Common: (1-9%)</p> <ul style="list-style-type: none"> ▪ Headache, fever, nausea, dizziness, fatigue, diarrhea, myalgia, oropharyngeal pain, upper abdominal pain. <p>Rare: (<1/1000) As with any immunization, unexpected or unusual side effects can occur.</p>

Note: Shake well before administration. Do not inject intradermally, subcutaneously or intravenously. Cold chain must be strictly observed, does not contain any preservatives or antibiotics. Protect from light.